CSTL Share Price Performance
US$32.33
10.71 (49.54%)
26.5% undervalued intrinsic discount
US$44.00
Fair Value
Price US$32.33
AnalystConsensusTarget US$44.00
AnalystLowTarget US$35.00
AnalystHighTarget US$56.72
Fair ValueUS$44.00
Share Pricen/a
Castle Biosciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
CSTL Community Narratives
AN
Fair Value
·Fair Value US$44 26.5% undervalued intrinsic discount
Expanding Diagnostic Menus Will Unlock Broad Clinical Potential
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$35 7.6% undervalued intrinsic discount
Payer Scrutiny And Coverage Risks Will Limit Long-Term Precision Dermatology Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$56.72 43.0% undervalued intrinsic discount
Atopic Dermatitis Opportunity And Expanding Test Adoption Will Transform Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Castle Biosciences
43.0% undervalued intrinsic discount
Atopic Dermatitis Opportunity And Expanding Test Adoption Will Transform Long Term Outlook
View narrativeAN
Updated 16 Aug
Castle Biosciences
26.5% undervalued intrinsic discount
Expanding Diagnostic Menus Will Unlock Broad Clinical Potential
View narrativeAN
Updated 25 Jun
Castle Biosciences
7.6% undervalued intrinsic discount
Payer Scrutiny And Coverage Risks Will Limit Long-Term Precision Dermatology Potential
View narrativeAN
Updated 9 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
CSTL: Stronger Test Adoption And Guidance Are Expected To Support Profitability
Fair Value: US$56.72 43.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Fair Value: US$35 7.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Fair Value: US$44 26.5% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Castle Biosciences, Inc. Key Details
About CSTL
- Founded
- 2007
- Employees
- 1002
- CEO
- WebsiteView website
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
